Silence Therapeutics PLC Further US patents granted (8740T)

TIDMSLN

RNS Number : 8740T

Silence Therapeutics PLC

18 October 2017

Further US patents granted

18 October 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the US Patent and Trade Mark Office yesterday granted US patent application 15/589,968 as US Patent 9,790,501 and US patent application 15/594,438 as US Patent 9,790,505.

Silence previously reported issuance of a notice of allowance for US patent application 15/589,968 on 15 August 2017 and for US patent application 15/594,438 on 11 September 2017.

The allowed claims of US Patents 9,790,501 and 9,790,505 will provide Silence with further protection for its innovative chemical modification technology in the US. Silence believes that these newly granted claims are relevant to third-party RNAi medicines, including Alnylam Pharmaceuticals' products such as Patisiran, Fitusiran, Inclisiran, Givosiran and Cemdisiran.

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:

"These grants provide further protection for our US patent estate. We now have ten granted US patents, one US patent application, three granted European patents and four European patent applications encompassing our chemical modification technology. Our chemical modification patent portfolio also encompasses patents and patent applications in the following countries: Australia, Brazil, Canada, China, Israel, India, Japan, Korea, Mexico and South Africa.

"We continue to believe that several third party late-stage RNAi candidates require licences under our chemical modification patent portfolio. This includes Alnylam Pharmaceuticals' products such as Patisiran, Fitusiran, Inclisiran, Givosiran and Cemdisiran."

Enquiries:

 
 Silence Therapeutics plc                Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive          3457 6900 
  Officer 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser        Tel: +44 (0)20 
  and Broker)                             7418 8900 
  James Steel/Oliver Jackson 
 Media Enquiries:                        Tel: +44 (0) 
  FTI Consulting                          20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBLBDGXXBBGRR

(END) Dow Jones Newswires

October 18, 2017 02:00 ET (06:00 GMT)